Table 4

Study quality assessment of prediction models when stroke is reported as a part of composite CV outcome and performance measure (C-statistic) is presented for the composite CV outcome

Study	Inclusion/ exclusion criteria specified	Non-biased selection	Missing value/loss to follow-up considered	Modelling assumptions satisfied	Model external validation	Outcome assessed without knowledge of the candidate predictors (ie, blinded)	Duration of follow-up long enough	Potential clinical use of the model discussed	Study limitations discussed
Brownrigg et al.15	Yes	No	No	No	No	Not clear	No	Yes	Yes
Khalili et al 50	Yes	No	No	Yes	No	Not clear	Yes	Yes	Yes
Cederholm et al 51	Yes	Not clear	No	Yes	No	Not clear	Yes	Yes	Yes
Davis et al 33	Not clear	Not clear	No	Yes	Yes	Not clear	No	No	No
Kengne et al 34	Yes	Yes	Not clear	Not clear	Yes	Not clear	No	Yes	Yes
Ofstad et al 25	Yes	Not clear	Yes	Yes	No	Not clear	Yes	Yes	Yes
Looker et al 52	Yes	Not clear	Yes	Not Clear	No	Not clear	No	Yes	Yes
Mukamal et al 32	Yes	Yes	Yes	Yes	Yes	Not Clear	Yes	Yes	Yes
Paynter et al 53	Yes	Yes	No	No	No	Not Clear	Yes	No	No
Price et al 54	Yes	Not clear	Not clear	No	No	Not clear	No	No	Yes
Selby et al 55	Yes	Yes	Yes	No	No	Not clear	No	Yes	Yes
Zethelius et al 35	Yes	Not clear	No	Yes	No	Not clear	No	Yes	Yes
Alrawahi et al 41	Yes	Yes	No	Yes	No	Not clear	Yes	Yes	Yes
Zarkogianni et al 56	No	Not clear	Not clear	Yes	No	Not clear	Yes	Yes	Yes
Price et al 57	Not clear	Yes	No	Not clear	No	Not clear	Yes	Yes	Yes
Wan et al 58	Yes	Yes	Yes	Yes	No	Not clear	Yes	Yes	Yes
Young et al 59	Yes	Yes	Not clear	Not clear	No	Not clear	Not clear	Yes	Yes
van der Leeuw et al 60	Yes	Not clear	Yes	Not clear	No	Not clear	Yes	Yes	Yes
Alshehry et al 61	Yes	Yes	Not clear	Not clear	No	Not clear	Yes	Yes	Yes
Woodward et al. The AD-ON Risk Score62	Yes	Yes	Not clear	Not clear	No	Not clear	Yes	Yes	Yes
Parrinello et al 63	Yes	Yes	No	Not clear	No	Not clear	Yes	Yes	Yes
Colombo et al 64	Yes	Yes	Yes	Not clear	No	Not clear	No	Yes	Yes
Elley et al. NZ DCS40	Yes	Not clear	Yes	Yes	Yes	Not clear	No	Yes	No

AD-ON, Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation-Observational; NZ DCS, New Zealand Diabetes Cohort Study.